CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Ca
CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer Center in New York presented results from a Phase II study with 98 patients randomised to receive an old drug, temozolomide, or selumetinib which inhibits the MEK pathway affected by GNAQ and GNA II gene mutations commonly found in this rare tumour. He discussed findings with Peter Goodwin.